Related Experiment Videos
Cyproterone acetate treatment in precocious puberty
Journal of Endocrinological Investigation
|July 1, 1981
Summary
Cyproterone acetate (CPA) effectively treated precocious puberty in girls, improving adult height prognosis. While generally safe, CPA showed adrenal suppressive effects in some patients.
Area of Science:
- Pediatric Endocrinology
- Reproductive Medicine
- Pharmacology
Background:
- Precocious puberty presents significant challenges in pediatric care.
- Idiopathic precocious puberty and McCune Albright syndrome require effective treatment strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of cyproterone acetate (CPA) in treating girls with precocious puberty.
- To assess the impact of CPA on clinical signs of puberty and hormonal profiles.
Main Methods:
- Seven girls with precocious puberty received cyproterone acetate (70 mg/M2/die) for 11-36 months.
- Clinical parameters (growth, bone age, pubertal development) and hormonal assays (basal and stimulated) were monitored.
- Evaluated efficacy and potential side effects, including adrenal function.
Main Results:
- Satisfactory regression of clinical signs of puberty was observed.
- Improved prognosis for adult height was indicated by an increased developmental quotient.
- No adrenal insufficiency symptoms, but CPA demonstrated adrenal suppressive effects in 4 patients.
Conclusions:
- Cyproterone acetate is an effective treatment for precocious puberty in girls.
- CPA treatment can positively influence adult height prediction.
- Monitoring for adrenal suppressive effects is recommended during CPA therapy.